PUK14 Cost-Effectiveness Analysis of Mirabegron Versus Tolterodine Extended Release in the Treatment of Patients With Overactive Bladder in the United States  by Xie, J. et al.
of aids, especially due to the lower pad usage. Patients treated with Trospium
chloride (€5,409) exhibited the highest costs using the general approach and pa-
tients treated with Tolterodine (€2,198) incurred the highest costs using the specific
approach. All results were highly significant (p0.01). CONCLUSIONS: This study
compares the costs of six anticholinergics for the treatment of OAB and inconti-
nence in Germany. OAB patients treated with Propiverine and incontinent patients
treated with Solifenacin have shown the lowest additional costs. For both patient
groups Tolterodine is associated with the highest additional cost of treatment.
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OBJECTIVES: Once daily tacrolimus (OD) revealed better compliance and adher-
ence in post-transplant patients compared to twice daily tacrolimus (BD). Higher
adherence on immunosuppressant therapy revealed lower rate of rejection, hence
lower consumption of dialysis and re-transplantation. We assessed cost-effective-
ness of tacrolimus OD vs. tacrolimus BD in treatment of post-renal transplant
patients in 15 year horizon. METHODS: We developed a Markov cohort model
(using TreAge PRO 2012) with 1-year cycle length with Life-Years-Gained (LYG) as
an outcome; the model reflects health insurances’ perspective. We used literature
derived time-dependent probabilities of transitions among particular health states
(incl. mortality). Patients enter the model after successful kidney transplantation.
We identified following health states: Graft survive, Acute graft rejection (AR),
Post-rejection, Dialysis, Re-transplantation. Patients may Die from each state. Drug
acquisition cost of tacrolimus OD was 10% higher compared to BD, other costs of AR
(1,799€), dialysis (33,675€) and transplantation (16,631€) were derived by an expert
panel and local pricing lists. The costs and outcomes were discounted by 3% rate.
We performed One-Way-Sensitivity (OWSA) and Probabilistic-Sensitivity (PSA)
analyses using 20% deviation from base-case. RESULTS: The model predictability,
in term of patients’ survival within 15 year horizon, was validated according to
mortality data in several kidney transplant patients’ registries. The deterministic
results in 15 year horizon showed that tacrolimus OD generated costs of 67,457€
(10.714 LYG) and tacrolimus BD 68,316€ (10.581 LYG), tacrolimus BD revealed incre-
mental costs of 859€ and -0.133 LYG. PSA showed 96.7% probability of tacrolimus
OD being dominant and 3.3% below defined threshold of 1 GDP/ capita in the Czech
Republic. CONCLUSIONS: Tacrolimus OD is dominant intervention (lower costs
and simultaneously higher outcomes) despite 10% higher acquisition costs com-
pared to tacrolimus BD. OWSA showed that the results were the most sensitive on
tacrolimus acquisition cost, compliance rate and cost of dialysis.
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OBJECTIVES: Standard of care and use of immunosuppressive drugs in renal trans-
plant recipients have changed in recent years. We provide an updated pharmaco-
economic model which uses state of the art methodological standards in phar-
macoeconomics based upon current evidence. To our knowledge this is the first
analysis in transplant medicine using a mixed treatment comparison (MTC)
analysis. METHODS: An established Markov model was updated comparing four
currently used immunosuppressive regimens (TR) which reflect real life use in
clinical transplant practice not necessarily restricted to an approved label: “Siroli-
mus  early withdrawal of Ciclosporin  Steroids” (TR1), “Sirolimus-early-transi-
tion” (TR2), “Everolimus-early-transition” (TR3) and “Tacrolimus low doseMyco-
phenolate mofetil Steroids” (TR4). Patients could experience nine different states
of post-transplant adverse events, discontinue TR or die. Transition probabilities
were based on a MTC analysis for a 12 month time horizon. Costs and benefits were
modeled from the perspective of the German statutory health insurance (SHI).
Robustness of the model was tested in extensive sensitivity analyses. RESULTS:
“Sirolimus early transition” (TR2) yields the highest life years (LY) (0.987 LY), while
generating costs of 17,500 Euro for 12 months, slightly more than TR4 (conservative
assumption). TR2 clearly dominates TR 3, a regimen with the second mTOR-inhib-
itor in market, and TR1, the regimen used in the European registration study, in
terms of ICER (incremental cost-effectiveness ratio) in Euro per LY gained for 12
months. Incremental costs of 1,096 Euro for TR2 in comparison to TR4 resulted in
an ICER of 548,000 Euro per QALY gained. CONCLUSIONS: The early transition to
Sirolimus yields favorable results compared to the majority of other regimens in-
vestigated in terms of patient survival and ICER per life year gained. The analysis
corroborates the feasibility of a MTC approach and reflects crucial outcomes which
may support informed clinical decision making.
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OBJECTIVES: There are evidences on the favorable nutritional effects of Ketosteril
in dialysis. Better quality of life and overall survival is attainable through improved
nutritional status, which is also proved in practice. Our aim was to evaluate the
cost-effectiveness of Ketodiet in dialysis in comparison with CKD treatment with-
out Ketosteril. A cohort calculation was presented on the basis of representative
patient attendance data from the Hungarian National Health Insurance Fund Ad-
ministration (HNHIFA). Main outcome of the analysis was incremental cost of life
years gained (LYG). METHODS: HNHIFA database uniquely contains detailed pro-
vision data from the whole Hungarian population of 10 million. All financed health
care providers use the same report structure and reported data are strictly vali-
dated. Our retrospective analyses included data of 2004-2009 for all dialysed pa-
tients with chronic kidney disease (ICD code N17-19) as main diagnosis. Altogether
13 615 patients’ data were included with a mean follow up of 53 months. Ctree●
function of party package in R statistical program was used to determine empirical
survival curves for patients treated with and without Ketosteril. Total costs of
health care services (in- and outpatient care, labs, diagnostics, drugs, medical aids
and sick leave) were taken into consideration. In case of death life years’ loss were
calculated on the basis of Hungarian life expectancy. Costs and outcomes were
discounted with official Hungarian rate of 5%. RESULTS: The average total cost per
patient was 9 596 € higher for Ketosteril arm (39 883 € vs 30 287 €). On the basis of
mortality data we determined lost life years, which showed 0,97 years favour to
Ketosteril (7,24 years vs 8,21 years). ICER of 3 509 460 HUF/LYG represents cost-
effectiveness of Ketosteril compared to other reimbursed health technologies in
Hungary. CONCLUSIONS: Ketosteril therapy of dialysis patients could be a cost-
effectiveness treatment choice based on real world data analysis of Hungarian
patients.
PUK14
COST-EFFECTIVENESS ANALYSIS OF MIRABEGRON VERSUS TOLTERODINE
EXTENDED RELEASE IN THE TREATMENT OF PATIENTS WITH OVERACTIVE
BLADDER IN THE UNITED STATES
Xie J1, Zhou ZY2, Bui CN3, Yan Y1, De G1, Runken MC4, Wu EQ2
1Analysis Group, Inc., New York, NY, USA, 2Analysis Group, Inc., Boston, MA, USA,
3Astellas Pharma US, Inc., Northbrook, IL, USA, 4Astellas Pharma US, Inc., Glenview, IL, USA
OBJECTIVES: To assess the cost-effectiveness associated with mirabegron versus
tolterodine extended release (ER) for treating overactive bladder (OAB) from a third
party payer perspective in the US. METHODS: A Markov model was developed to
follow a cohort of OAB patients treated with mirabegron versus tolterodine ER for a
one-year period. Three health states were defined - normal: number of inconti-
nence (I)0 and number of micturitions (M)8; mild-to-moderate: 0I6 and
M16, or I0 and 8 M16; severe: I6 and M16. Evidence from a 12-week clin-
ical trial, comparing mirabegron 50 mg to tolterodine ER 4 mg, was used to estimate
the initial health state distribution, transition probabilities, and discontinuation
rates. Only direct costs were considered, including drug costs (2012 USD) and costs
for OAB complications (2011 USD), with inputs from ReadyPrice® and published
literature. Effectiveness was defined as the proportion of patients in normal state.
Results were expressed as the incremental cost per patient in normal state at the
end of one-year. A subgroup analysis was conducted for patients who discontinued
prior antimuscarinic therapy due to insufficient efficacy at baseline. Univariate and
probabilistic sensitivity analyses were performed. RESULTS: For a one-year hori-
zon, the incremental cost per patient in normal state associated with mirabegron
vs. tolterodine ER was $5,580 (total cost of $4,707 and $4,420 and effectiveness of
17.72% and 12.57% for mirabegron and tolterodine ER respectively) for the total
population. For the subgroup, the incremental cost per patient in normal state was
$2,734 (total cost of $4,664 and $4,451 and effectiveness of 12.76% and 4.96% for
mirabegron and tolterodine ER respectively). Results were robust to the model
assumptions and inputs, while drug cost was the main driver of the model.
CONCLUSIONS: Mirabegron is expected to be a cost-effective option compared to
tolterodine ER, particularly in patients who discontinued prior antimuscarinic
therapy due to insufficient efficacy.
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OBJECTIVES: The INDEPENDENT study showed for the first time a significant re-
duction in mortality associated with Sevelamer, a phosphate binder, compared to
Calcium Carbonate, in stage 3-4 nondialysis-dependent CKD patients. We evalu-
ated the impact on CKD related hospitalizations in order to assess the cost-effec-
tiveness profile from the NHS perspective. METHODS: The INDEPENDENT study
involved 107 (Sev) and 105 (CaC) patients with a 36 months follow-up. Since few of
them started dialysis, we also performed a subgroup secondary analysis on pa-
tients remaining dialysis free (76 vs 63). Individual hospitalizations in Nephrology,
Cardiology and ICU were recorded as well the overall length of stay over the obser-
vation period. Correlated consumption of drugs, such as alpha and beta blockers,
ARBs, ACE inhibitors, calcium channels blockers and erythropoietin, was also as-
sessed. For hospitalizations and drugs, DGR tariffs and hospital acquisition cost
respectively were used. As effectiveness end-point we considered the number of
averted deaths. RESULTS: Calcium-treated patients were associated with greater
frequencies of admission in all departments, thus generating significantly higher
costs. The average savings generated by reduced hospitalizations far exceeded the
acquisition cost of Sevelamer. In case of hospitalization, Sevelamer-treated pa-
tients showed a substantial reduction in the overall length of stay (-5.9 days,
p0.012). Such difference was also present in the secondary subgroup (-5.5 days,
p0.13). After 1000 bootstrap sampling, the primary analysis provided a mean cost
difference of -€2282/ €27 (CI 95%) and mean effectiveness difference of 0.09/
0.006 averted deaths in favor of Sevelamer. Similar figures were present in the
secondary subgroup analysis (-€2403 / €28 and 0.15 / 0.007). Sevelamer
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